Hydroxychloroquine in systemic lupus erythematosus (SLE)

References

• Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013;43(2):264–272.
   PubMed Web of Science ®Google Scholar
• Mindell JA. Lysosomal acidification mechanisms. Annu Rev Physiol. 2012;74:69–86.
   PubMed Web of Science ®Google Scholar
• Hurst NP, French JK, Gorjatschko L, et al. Chloroquine and hydroxychloroquine inhibits multiple sites in metabolic pathways leading to neutrophil superoxide release. J Rheumatol. 1988;15(1):23–27.
   PubMed Web of Science ®Google Scholar
• Kaufmann AM, Krise JP. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci. 2007;96(4):729–746.
   PubMed Web of Science ®Google Scholar
• Settembre C, Malta D, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332:1429–1433.
   PubMed Web of Science ®Google Scholar
• Ghodke-Puranik Y, Niewold TB. Immunogenetics of systemic lupus erythematosus: a comprehensive review. J Autoimmun. 2015;64:125–136.
   PubMed Web of Science ®Google Scholar
• Bijl M, Kallenberg CG. Ultraviolet light and cutaneous lupus. Lupus. 2006;15:724–727.
   PubMed Web of Science ®Google Scholar
• Draborg AH, Duus K, Houen G. Epstein-barr virus and systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:370516.
   PubMedGoogle Scholar
• Simard JF, Costenbader KH, Liang MH, et al. Exposure to maternal smoking and incident SLE in a prospective cohort study. Lupus. 2009;18:431–435.
   PubMed Web of Science ®Google Scholar
• Fadeel B, Xue D, Kagan V. Programmed cell clearance: molecular regulation of the elimination of apoptotic cell corpses and its role in the resolution of inflammation. Biochem Biophys Res Commun. 2010;396(1):7–10.
   PubMed Web of Science ®Google Scholar
• Fenton K. The effect of cell death in the initiation of lupus nephritis. Clin Exp Immunol. 2015;179(1):11–16.
   PubMed Web of Science ®Google Scholar
• Niewold TB, Clark DN, Salloum R, et al. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:948364.
   PubMedGoogle Scholar
• Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus -an update. Curr Opin Immunol. 2012;24(6):651–657.
   PubMed Web of Science ®Google Scholar
• Moody KL, Uccellini MB, Avalos AM, et al. Toll-like receptor-dependent immune complex activation of B cells and dendritic cells. Methods Mol Biol. 2016;1390:249–272.
   PubMedGoogle Scholar
• Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res. 2011;31:887–892.
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294:1540–1543.
   PubMed Web of Science ®Google Scholar
• Lamphier M, Zheng W, Latz E, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014;85(3):429–440.
   PubMed Web of Science ®Google Scholar
• Crispin JC, Kyttaris VC, Terhorst C, et al. T cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:317–325.
   PubMed Web of Science ®Google Scholar
• Jenks SA, Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev. 2009;8(3):209–213.
   PubMed Web of Science ®Google Scholar
• Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol. 2011a;32(8):388–394.
   PubMed Web of Science ®Google Scholar
• Codogno P, Mehrpour M, Proikas-Cezanne T. Canonical and non-canonical autophagy: variations on a common theme of self-eating? Nat Rev Mol Cell Biol. 2011;13:7–12.
   PubMed Web of Science ®Google Scholar
• Levine B, Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol. 2007;7(10):767–777.
   PubMed Web of Science ®Google Scholar
• Wang L, Law HK. The role of autophagy in lupus nephritis. Int J Mol Sci. 2015;16(10):25154–25167.
   PubMed Web of Science ®Google Scholar
• Gros F, Arnold J, Page N, et al. Macroautophagy is deregulated in murine and human lupus T lymphocytes. Autophagy. 2012;8(7):1113–1123.
   PubMed Web of Science ®Google Scholar
• Clarke AJ, Ellinghaus U, Cortini A, et al. Autophagy is activated in systemic lupus erythematosus and required for plasmablast development. Ann Rheum Dis. 2015;74(5):912–920.
   PubMed Web of Science ®Google Scholar
• Martinez J, Cunha LD, Park S, et al. Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature. 2016;533(7601):115–119.
   PubMed Web of Science ®Google Scholar
• Huang QQ, Pope RM. The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep. 2009;11(5):357–364.
   PubMedGoogle Scholar
• Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794–4804.
   PubMed Web of Science ®Google Scholar
• Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 1996;5(Suppl 1):S4–S10.
   PubMed Web of Science ®Google Scholar
• Kalish RS, Koujak S. Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations. Clin Immunol. 2004;113(3):270–277.
   PubMed Web of Science ®Google Scholar
• Wozniacka A, Lesiak A, Boncela J, et al. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dermatol. 2008;159(5):1124–1130.
   PubMed Web of Science ®Google Scholar
• Goldman FD, Gilman AL, Hollenback C, et al. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood. 2000;95(11):3460–3466.
   PubMed Web of Science ®Google Scholar
• Lotze MT, Maranchie J, Appleman L. Inhibiting autophagy: a novel approach for the treatment of renal cell carcinoma. Cancer J. 2013;19(4):341–347.
   PubMed Web of Science ®Google Scholar
• Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112(5):1687–1695.
   PubMed Web of Science ®Google Scholar
• Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010;115(11):2292–2299.
   PubMed Web of Science ®Google Scholar
• Rainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231–269.
   PubMed Web of Science ®Google Scholar
• Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996;5(Suppl 1):S11–S15.
   PubMed Web of Science ®Google Scholar
• Wasko MC, McClure CK, Kelsey SF, et al. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015;58(10):2336–2343.
   PubMed Web of Science ®Google Scholar
• Tett SE, Cutler DJ, Beck C, et al. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis–a prospective, dose ranging study. J. Rheumatol. 2000;27:1656–1660.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:3284–3290.
   PubMed Web of Science ®Google Scholar
• Durcan L, Clarke WA, Magder LS, et al. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42(11):2092–2097.
   PubMed Web of Science ®Google Scholar
• Tye MJ, White H, Appel B, et al. Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine. N Engl J Med. 1959;260(2):63–66.
   PubMed Web of Science ®Google Scholar
• Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;4:CD002954.
   Google Scholar
• Yokogawa N, Tanikawa A, Amagai M, et al. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol. 2013;23(2):318–322.
   PubMed Web of Science ®Google Scholar
• Francès C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. 2012;148(4):479–484.
   PubMedGoogle Scholar
• Chasset F, Arnaud L, Costedoat-Chalumeau N, et al. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study. J Am Acad Dermatol. 2016;74(4):693–699.
   PubMed Web of Science ®Google Scholar
• Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–381.
   PubMed Web of Science ®Google Scholar
• Ben-Zvi I, Kivity S, Langevitz P, et al. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42:145–153.
   PubMed Web of Science ®Google Scholar
• Petri M. Hydroxychloroquine use in the baltimore lupus cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5(Suppl 1):S16–22.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Linker-Israeli M, Metzger AL, et al. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus. 1993;2(Suppl 1):S13–S15.
   PubMed Web of Science ®Google Scholar
• Mok CC, Penn HJ, Chan KL, et al. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res (Hoboken). 2016;68(9):1295–1302.
   PubMed Web of Science ®Google Scholar
• Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011;13(1):77–80.
   PubMed Web of Science ®Google Scholar
• Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol. 2013;40(1):30–33.
   PubMed Web of Science ®Google Scholar
• Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev. 2015;14(4):358–362.
   PubMed Web of Science ®Google Scholar
• Gerosa M, Meroni PL, Erkan D. Recognition and management of antiphospholipid syndrome. Curr Opin Rheumatol. 2016;28(1):51–59.
   PubMed Web of Science ®Google Scholar
• Khamashta MA, Buchanan NM, Hughes GR. The use of hydroxychloroquine in lupus pregnancy: the British experience. Lupus. 1996;5(Suppl 1):S65–6.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640–3647.
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Blyakhman S, Shechtman S, et al. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol. 2013;39:58–62.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Moroni G. Immunosuppression in pregnant women with systemic lupus erythematosus. Expert Rev Clin Immunol. 2015;11(5):549–552.
   PubMed Web of Science ®Google Scholar
• Moroni G, Ponticelli C. Pregnancy in women with systemic lupus erythematosus (SLE). Eur J Intern Med. 2016;32:7–12.
   PubMed Web of Science ®Google Scholar
• Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14(2):106–112.
   PubMedGoogle Scholar
• Stoyan G, Petri M. Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol. 2013;62(3):255–262.
   PubMed Web of Science ®Google Scholar
• Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford). 2015;54(7):1244–1249.
   PubMed Web of Science ®Google Scholar
• Bourke L, McCormick J, Taylor V, et al. Hydroxychloroquine protects against cardiac ischaemia/reperfusion injury in vivo via enhancement of ERK1/2 Phosphorylation. Plos One. 2015;10(12):e0143771.
   PubMed Web of Science ®Google Scholar
• Virdis A, Tani C, Duranti E, et al. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Res Ther. 2015;17:277.
   PubMed Web of Science ®Google Scholar
• Gómez-Guzmán M, Jiménez R, Romero M, et al. Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. Hypertension. 2014;64(2):330–337.
   PubMed Web of Science ®Google Scholar
• Sun L, Liu M, Li R, et al. Hydroxychloroquine, a promising choice for coronary artery disease? Med Hypotheses. 2016;93:5–7.
   PubMed Web of Science ®Google Scholar
• Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINAL). Ann Rheum Dis. 2007;66(9):1168–1172.
   PubMed Web of Science ®Google Scholar
• Akhavan PS, Su J, Lou W, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013;40(6):831–841.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–28.
   PubMed Web of Science ®Google Scholar
• Wang JM, Li JY, Huang WC, et al. Confirmed false positive proteinuria in patients with systemic lupus erythematosus taking hydroxychloroquine: a spot sample measurement. Clin Lab. 2015;61(5–6):581–586.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Dunogué B, Morel N, et al. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med. 2014;43:e167–80.
   PubMed Web of Science ®Google Scholar
• Smith ER, Klein-Schwartz W. Are 1-2 dangerous? chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med. 2005;28(4):437–443.
   PubMed Web of Science ®Google Scholar
• Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol. 1990;25(5):249–251.
   PubMed Web of Science ®Google Scholar
• Brandao LM, Palmowski-Wolfe AM. A possible early sign of hydroxychloroquine macular toxicity. Doc Ophthalmol. 2016;132(1):75–81.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TY, et al., American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–1394.
   PubMed Web of Science ®Google Scholar
• Joyce E, Aurelie Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care. 2013;2(1):77–83.
   PubMedGoogle Scholar
• Baguet JP, Tremel F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. Heart. 1999;81:221–223.
   PubMed Web of Science ®Google Scholar
• Nord JE, Shah PK, Rinaldi RZ, et al. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum. 2004;33:336–351.
   PubMed Web of Science ®Google Scholar
• Tönnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy - a review of the literature. Immunopharmacol Immunotoxicol. 2013;35(3):434–442.
   PubMed Web of Science ®Google Scholar
• Roos JM, Aubry MC, Edwards WD. Chloroquine cardiotoxicity: clinicopathologic features in three patients and comparison with three patients with fabry disease. Cardiovasc Pathol. 2002;11(5):277–283.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Hulot JS, Amoura Z, et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology. 2007;107:73–80.
   PubMed Web of Science ®Google Scholar
• Soria A, Barbaud A, Assier H, et al. Cutaneous adverse drug reactions with antimalarials and allergological skin tests. Dermatology. 2015;231(4):353–359.
   PubMed Web of Science ®Google Scholar
• Callaly EL, FitzGerald O, Rogers S. Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis. Clin Exp Dermatol. 2008;33(5):572–574.
   PubMed Web of Science ®Google Scholar
• Murphy M, Carmichael AJ. Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol. 2001;26(5):457–458.
   PubMed Web of Science ®Google Scholar
• Cameron MC, Word AP, Dominguez A. Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus. Dermatol Online J. 2014;20:11.
   PubMedGoogle Scholar
• Jallouli M, Francès C, Piette JC, et al. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol. 2013;149(8):935–940.
   PubMed Web of Science ®Google Scholar
• Malcangi G, Fraticelli P, Palmieri C, et al. Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. Rheumatol Int. 2000;20(1):31–33.
   PubMed Web of Science ®Google Scholar
• Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol. 2000;27(12):2927–2931.
   PubMed Web of Science ®Google Scholar
• Siddiqui AK, Huberfeld SI, Weidenheim KM, et al. Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest. 2007;131(2):588–590.
   PubMed Web of Science ®Google Scholar
• Kwon JB, Kleiner A, Ishida K, et al. Hydroxychloroquine-induced myopathy. J Clin Rheumatol. 2010;16(1):28–31.
   PubMed Web of Science ®Google Scholar
• Good MI, Shader RI. Behavioral toxicity and equivocal suicide associated with chloroquine and its derivatives. Am J Psychiatry. 1977;134(7): 798–601.
   PubMed Web of Science ®Google Scholar
• Makin AJ, Wendon J, Fitt S, et al. Fulminant hepatic failure secondary to hydroxychloroquine. Gut. 1994;35(4):569–570.
   PubMed Web of Science ®Google Scholar
• Giner Galvañ V, Oltra MR, Rueda D, et al. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. Clin Rheumatol. 2007;26(6):971–972.
   PubMed Web of Science ®Google Scholar
• Abdel Galil SM. Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report. Lupus. 2015;24(6):638–640.
   PubMed Web of Science ®Google Scholar
• Angelakis E, Million M, Kankoe S, et al. Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. Antimicrob Agents Chemother. 2014;58(6):3342–3347.
   PubMed Web of Science ®Google Scholar
• Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.
   PubMed Web of Science ®Google Scholar
• Moroni G, Quaglini S, Gallelli B, et al. Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years. Lupus. 2013;22(8):810–818.
   PubMed Web of Science ®Google Scholar
• Harvey PR, Gordon C. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. BioDrugs. 2013;27(2):85–95.
   PubMed Web of Science ®Google Scholar
• Mok CC. Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis. 2015;18(2):154–163.
   PubMed Web of Science ®Google Scholar